Literature DB >> 29229507

Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors.

Mona Kamal1, David I Rosenthal2, Stefania Volpe3, Ryan P Goepfert4, Adam S Garden2, Katherine A Hutcheson4, Karine A Al Feghali5, Mohamed Ahmed Mohamed Meheissen6, Salman A Eraj7, Amy E Dursteler7, Bowman Williams2, Joshua B Smith7, Jeremy M Aymard8, Joel Berends9, Aubrey L White7, Steven J Frank2, William H Morrison2, Richard Cardoso4, Mark S Chambers4, Erich M Sturgis10, Tito R Mendoza11, Charles Lu11, Abdallah S R Mohamed12, Clifton D Fuller13, G Brandon Gunn14.   

Abstract

PURPOSE: To identify a clinically meaningful cut-point for the single item dry mouth question of the MD Anderson Symptom Inventory-Head and Neck module (MDASI-HN).
METHODS: Head and neck cancer survivors who had received radiation therapy (RT) completed the MDASI-HN, the University of Michigan Hospital Xerostomia Questionnaire (XQ), and the health visual analog scale (VAS) of the EuroQol Five Dimension Questionnaire (EQ-5D). The Bayesian information criteria (BIC) were used to test the prediction power of each tool for EQ-5D VAS. The modified Breiman recursive partitioning analysis (RPA) was used to identify a cut point of the MDASI-HN dry mouth score (MDASI-HN-DM) with EQ-5D VAS, using a ROC-based approach; regression analysis was used to confirm the threshold effect size.
RESULTS: Two-hundred seven respondents formed the cohort. Median follow-up from the end of RT to questionnaire completion was 88 months. The single item MDASI-HN-DM score showed a linear relationship with the XQ composite score (ρ = 0.80, p < 0.001). The MDASI-HN-DM displayed improved model performance for association with EQ-5D VAS as compared to XQ (BIC of 1803.7 vs. 2016.9, respectively). RPA showed that an MDASI-HN-DM score of ≥6 correlated with EQ-5D VAS decline (LogWorth 5.5).
CONCLUSION: The single item MDASI-HN-DM correlated with the multi-item XQ and performed favorably in the prediction of QOL. A MDASI-HN-DM cut point of ≥6 correlated with decline in QOL.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dry mouth; Head and neck; Patient reported outcomes; Prediction model; Quality of life; Survivors

Mesh:

Year:  2017        PMID: 29229507      PMCID: PMC5957088          DOI: 10.1016/j.radonc.2017.10.037

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  20 in total

Review 1.  Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): searching for standards.

Authors:  Charles S Cleeland; Jeff A Sloan
Journal:  J Pain Symptom Manage       Date:  2010-06       Impact factor: 3.612

2.  Radiotherapy: IMRT reduces xerostomia and potentially improves QoL.

Authors:  Avraham Eisbruch
Journal:  Nat Rev Clin Oncol       Date:  2009-10       Impact factor: 66.675

3.  Development of a head and neck companion module for the quality of life-radiation therapy instrument (QOL-RTI)

Authors:  A Trotti; D J Johnson; C Gwede; L Casey; B Sauder; A Cantor; J Pearlman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-09-01       Impact factor: 7.038

4.  High symptom burden prior to radiation therapy for head and neck cancer: a patient-reported outcomes study.

Authors:  G Brandon Gunn; Tito R Mendoza; Clifton D Fuller; Ibrahima Gning; Steven J Frank; Beth M Beadle; Ehab Y Hanna; Charles Lu; Charles S Cleeland; David I Rosenthal
Journal:  Head Neck       Date:  2012-11-20       Impact factor: 3.147

5.  [EuroQol-5D (EQ-5D): an instrument for measuring quality of life].

Authors:  Gianluigi Balestroni; Giorgio Bertolotti
Journal:  Monaldi Arch Chest Dis       Date:  2012-09

6.  Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer.

Authors:  A Eisbruch; H M Kim; J E Terrell; L H Marsh; L A Dawson; J A Ship
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-01       Impact factor: 7.038

7.  Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy.

Authors:  B S Henson; M R Inglehart; A Eisbruch; J A Ship
Journal:  Oral Oncol       Date:  2001-01       Impact factor: 5.337

8.  Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study.

Authors:  G Brandon Gunn; Chase C Hansen; Adam S Garden; Clifton D Fuller; Abdallah S R Mohamed; William H Morrison; Steven J Frank; Beth M Beadle; Jack Phan; Gregory M Chronowski; Erich M Sturgis; Carol M Lewis; Charles Lu; Kate A Hutcheson; Tito R Mendoza; Charles S Cleeland; David I Rosenthal
Journal:  Radiother Oncol       Date:  2015-09-21       Impact factor: 6.280

9.  The M. D. Anderson symptom inventory-head and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis.

Authors:  David I Rosenthal; Tito R Mendoza; Mark S Chambers; V Shannon Burkett; Adam S Garden; Amy C Hessell; Jan S Lewin; K Kian Ang; Merrill S Kies; Ibrahima Gning; Xin S Wang; Charles S Cleeland
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-22       Impact factor: 7.038

10.  Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer.

Authors:  Aaron D Falchook; Rebecca Green; Mary E Knowles; Robert J Amdur; William Mendenhall; David N Hayes; Juneko E Grilley-Olson; Jared Weiss; Bryce B Reeve; Sandra A Mitchell; Ethan M Basch; Bhishamjit S Chera
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2016-06-01       Impact factor: 6.223

View more
  6 in total

1.  Physical symptoms in long-term survivors of rare cancer.

Authors:  Nora K Horick; Ariela Muzikansky; Hilda L Gutierrez; Kristina L Boyd; Dianne M Finkelstein
Journal:  J Cancer Surviv       Date:  2018-10-12       Impact factor: 4.442

2.  Priorities of human papillomavirus-associated oropharyngeal cancer patients at diagnosis and after treatment.

Authors:  Melina J Windon; Carole Fakhry; Farhoud Faraji; Tanya Troy; Christine G Gourin; Ana P Kiess; Wayne Koch; David W Eisele; Gypsyamber D'Souza
Journal:  Oral Oncol       Date:  2019-06-04       Impact factor: 5.337

3.  A prospective study of patient-reported xerostomia-related outcomes after parotidectomy.

Authors:  Kara D Brodie; Aaron L Zebolsky; Edgar Ochoa; Patrick K Ha; Chase M Heaton; Ivan H El-Sayed; William R Ryan
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-05-29

4.  Intensity-modulated proton therapy for oropharyngeal cancer reduces rates of late xerostomia.

Authors:  Jianzhong Cao; Xiaodong Zhang; Bo Jiang; Jiayun Chen; Xiaochun Wang; Li Wang; Narayan Sahoo; X Ronald Zhu; Rong Ye; Pierre Blanchard; Adam S Garden; C David Fuller; G Brandon Gunn; Steven J Frank
Journal:  Radiother Oncol       Date:  2021-04-08       Impact factor: 6.901

5.  Determinants of patient-reported xerostomia among long-term oropharyngeal cancer survivors.

Authors:  Puja Aggarwal; Katherine A Hutcheson; Adam S Garden; Frank E Mott; Charles Lu; Ryan P Goepfert; Clifton D Fuller; Stephen Y Lai; G Brandon Gunn; Mark S Chambers; Erich M Sturgis; Ehab Y Hanna; Sanjay Shete
Journal:  Cancer       Date:  2021-08-06       Impact factor: 6.860

6.  Mastication, swallowing, and salivary flow in patients with head and neck cancer: objective tests versus patient-reported outcomes.

Authors:  Jorine A Vermaire; Cornelis P J Raaijmakers; Irma M Verdonck-de Leeuw; Femke Jansen; C René Leemans; Chris H J Terhaard; Caroline M Speksnijder
Journal:  Support Care Cancer       Date:  2021-06-25       Impact factor: 3.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.